JOHN HOPE FRANKLIN CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1838-01-01

Employees: 5K

Market Cap: -

Website: http://www.duke.edu

Clinical Trials

Microvascular and Fibrosis Imaging Study

Completed

Conditions: Autoimmune Diseases
Chronic Graft Versus Host Disease
Sickle Cell Disease

Interventions: Other: Acoustic Radiation Force Impulse (ARFI)
Other: Laser Doppler Flowmetry (LDF)
Other: Laser Doppler Perfusion Imaging (LDI)
Other: Optical Coherence Tomography (OCT)
Other: Orthogonal Polarization Spectral Imaging (OPSI)
Other: Nail fold video capillaroscopy (NVC)

First Posted Date: 2013-01-01

Last Posted Date: 2020-09-11

Lead Sponsor: Duke University

Target Recruit Count: 63

Registration Number: NCT01758250

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Improving Decision Making for Patients With Prolonged Mechanical Ventilation

Not Applicable

Completed

Conditions: Prolonged Mechanical Ventilation
Surrogate Decision Makers

Interventions: Other: Usual care
Behavioral: Decision aid

First Posted Date: 2012-12-17

Last Posted Date: 2019-05-02

Lead Sponsor: Duke University

Target Recruit Count: 416

Registration Number: NCT01751061

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Duke University, Durham, North Carolina, United States

and more 1 locations

Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia

Completed

Conditions: Bronchopulmonary Dysplasia
Prematurity

First Posted Date: 2012-12-12

Last Posted Date: 2024-04-12

Lead Sponsor: Duke University

Target Recruit Count: 260

Registration Number: NCT01748565

Locations: 🇺🇸
Riley Children's Hospital, Indianapolis, Indiana, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis

Recruiting

Conditions: Sarcoidosis

First Posted Date: 2012-12-10

Last Posted Date: 2023-12-12

Lead Sponsor: Duke University

Target Recruit Count: 27000

Registration Number: NCT01745237

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Bevacizumab Beyond Progression (BBP)

Phase 2

Completed

Conditions: Glioblastoma
Grade 4 Malignant Glioma
Malignant Glioma
Gliosarcoma

Interventions: Radiation: Radiation Therapy
Drug: Temozolomide
Drug: Bevacizumab

First Posted Date: 2012-12-04

Last Posted Date: 2021-01-26

Lead Sponsor: Duke University

Target Recruit Count: 68

Registration Number: NCT01740258

Locations: 🇺🇸
Duke Cancer Center, Durham, North Carolina, United States

Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients

Phase 2

Completed

Conditions: Adult Brain Tumor
Malignant Glioma
Recurrent Glioblastoma Multiforme

Interventions: Drug: Vorinostat
Drug: Bevacizumab

First Posted Date: 2012-11-30

Last Posted Date: 2017-03-06

Lead Sponsor: Duke University

Target Recruit Count: 48

Registration Number: NCT01738646

Locations: 🇺🇸
Duke Cancer Center, Durham, North Carolina, United States

Improving Motorcycle Taxi Driver Visibility in Tanzania

Not Applicable

Completed

Conditions: Accidents, Traffic

Interventions: Other: Free reflective, fluorescent vest
Behavioral: Education

First Posted Date: 2012-11-27

Last Posted Date: 2013-08-09

Lead Sponsor: Duke University

Target Recruit Count: 180

Registration Number: NCT01733537

Locations: 🇹🇿
Kilimanjaro Region, Tanzania, Kilimanjaro Region, Tanzania

Sedative Effects in Obstructive Sleep Apnea

Phase 2

Withdrawn

Conditions: Obstructive Sleep Apnea

Interventions: Drug: Placebo
Drug: Dexmedetomidine

First Posted Date: 2012-11-26

Last Posted Date: 2015-03-04

Lead Sponsor: Duke University

Registration Number: NCT01733043

Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias

Completed

Conditions: Alzheimer's Disease
Dementias

First Posted Date: 2012-11-21

Last Posted Date: 2014-04-22

Lead Sponsor: Duke University

Target Recruit Count: 40

Registration Number: NCT01730430

Locations: 🇺🇸
Duke Health Center at Morreene Road, Durham, North Carolina, United States

Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Velcade
Drug: Cyclophosphamide
Drug: Revlimid

First Posted Date: 2012-11-20

Last Posted Date: 2017-05-31

Lead Sponsor: Duke University

Target Recruit Count: 17

Registration Number: NCT01729338

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy